Question 1

Why are isogenic controls considered the standard?

Accepted Answer

Lines from different people differ across the whole genome, so a phenotype seen between patient and unrelated control lines may reflect background rather than the variant. Correcting the variant in a patient line, or introducing it into a control line, produces a pair matched everywhere else and makes the attribution defensible.

Question 2

What line qualification is needed and how often?

Accepted Answer

Check genomic integrity by karyotype or copy number analysis, confirm identity against the donor sample, verify pluripotency markers and absence of reprogramming vectors, and screen for contamination. Repeat integrity checks periodically, because culture selects for changes that improve growth and these accumulate silently over passages.

Question 3

How many lines does a disease modelling study need?

Accepted Answer

One pair rarely convinces. Use several donors per group where the variant allows, or several independently edited clones per line, and treat lines rather than wells as the unit of replication. Report how many lines, clones and independent differentiation runs contributed to each result.

Question 4

What does screening require beyond a working protocol?

Accepted Answer

Large uniform batches, cryopreservation that survives thawing directly into assay plates, and demonstrated consistency across plates and batches. Calculate a separation statistic between controls on the actual readout, and confirm the phenotype is stable across the assay window, since a protocol adequate for imaging a few wells often fails at screening scale.

Question 5

How is residual undifferentiated material detected?

Accepted Answer

Sensitive assays for pluripotency transcripts and surface markers are needed, since a small remaining fraction carries teratoma risk in transplantation contexts. Report the detection limit achieved. Selective removal approaches include sorting on a lineage marker, metabolic selection, or agents that eliminate residual pluripotent cells.

Question 6

Why do derived cells often remain immature?

Accepted Answer

Most protocols recapitulate development only to a foetal-like stage, which limits modelling of late-onset conditions. Extended culture, metabolic and mechanical conditioning, co-culture with supporting cells and transplantation into an animal host all push maturity further. State the maturity reached rather than implying adult equivalence.

Question 7

What governance applies to donor-derived lines?

Accepted Answer

Consent must cover derivation, indefinite storage, genetic analysis, sharing with other groups and possible commercial use, and it should be settled before collection. Institutional oversight for stem cell work applies, and any therapeutic route adds sourcing and manufacturing requirements that shape decisions taken years earlier.

Biotechnology

Biotechnology

Research Frontiers in Directed Differentiation of iPSCs